March 20, 2026 by Mohr Marketing
Scammer Scrubβ’ vs. The Phantom Lead: Protecting the Integrity of the Legal Profession In the legal world, the term “bad data” is often treated as a minor annoyanceβan overhead cost of doing business. But for a personal injury firm looking to scale, “bad data” is a predatory threat. Whether it is bot-generated inquiries, professional “claim-fillers,”…
Continue reading Stop Phantom Leads: How Scammer Scrubβ’ Protects Your Law Firm
March 19, 2026 by Mohr Marketing
The Ethics of Case Acquisition: Why the “Service-Based Model” is the Future of Bar Compliance For the growth-minded personal injury attorney, the term “lead generation” often carries a double-edged sword. On one side is the necessity of a steady stream of new cases; on the other is the persistent anxiety over State Bar rules regarding…
Continue reading Why the ‘Service-Based Model’ is the Future of Bar Compliance”?
March 18, 2026 by Mohr Marketing
Mohr Marketing, LLC Redefines Legal Marketing Compliance with Nationwide Launch of βEvidence-Firstβ Acquisition Platform Sets 2026 Benchmark for Data Ethics, AI Verification, and State Bar Transparency in Personal Injury Law ALLENTOWN, PA β March 13, 2026 β Mohr Marketing, LLC, the nationβs leading innovator in compliant legal intake and marketing infrastructure, today announced the national…
Continue reading Evidence-First Legal Marketing Platform Redefines Compliance
March 17, 2026 by Mohr Marketing
Navigating the DPPA: How “Evidence-First” Marketing Respects Federal Privacy Laws In the modern legal landscape, data is the engine of growth. However, for personal injury attorneys, that engine often comes with a warning light: the Driverβs Privacy Protection Act (DPPA). Many firms shy away from innovative data strategies because they fear the regulatory repercussions of…
Continue reading DPPA Compliance in Legal Marketing: An Evidence-First Approach
March 16, 2026 by Mohr Marketing
Safeguarding Your Firmβs Depo-Provera (MDL 3140) Inventory As the pharmaceutical liability landscape shifts toward MDL 3140 (In re: Depo-Provera Products Liability Litigation), many firms are facing a critical operational choice: build volume quickly or build volume correctly. While the potential plaintiff pool for Depo-Provera is massiveβestimated at 74 million women worldwideβthe clinical criteria required to…
Continue reading Building Your MDL 3140 Portfolio with Precision
March 15, 2026 by Mohr Marketing
Donβt settle for “intake noise.” Leverage our Compliance Shield protocol to acquire signed plaintiffs with 12+ months of usage and imaging-confirmed Intracranial Meningiomas. The Opportunity: Why Pfizer (MDL 3140) Now? Massive Solvency: Unlike other defendants, Pfizer holds immense liquidity, ensuring the “muscle” to absorb global settlements. Scientific Catalyst: A March 2024 BMJ study revealed a…
Continue reading Build a High-Value Depo-Provera Docket with Verified, Audit-Ready Retainers
March 14, 2026 by Mohr Marketing
Depo-Provera MDL Science-Back Intake: How We Filter for the “5.6x Risk” Cohort The catalyst for the Depo-Provera MDL was a bombshell study published in the British Medical Journal (BMJ) in March 2024. That study didn’t just suggest a link; it identified a specific 5.6-fold increased risk of developing meningiomas for women using the drug for…
Continue reading Depo-Provera MDL – How We Filter for the “5.6x Risk” Cohort
March 13, 2026 by Mohr Marketing
The $3B Liquidity Advantage: Why Depo-Provera is the Strategic Play for 2025-2026 As many mass torts face defendants with thinning capital, the Depo-Provera litigation stands out for its defendant solvency. Pfizer holds massive liquidity, providing the “muscle” to absorb a global settlement without the existential risks seen in other recent litigations. A Mature Docket with…
Continue reading Why Depo-Provera is the Strategic Play for 2025-2026
March 12, 2026 by Mohr Marketing
Beyond “Intake Noise”: Why Precision is the Only Way to Build a Depo-Provera Docket The pharmaceutical liability landscape has shifted with the emergence of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the numbers are massiveβan estimated 74 million users worldwideβthe legal viability of these cases hinges on a level of medical precision that…
Continue reading Why Precision is the Only Way to Build a Depo-Provera Docket
March 11, 2026 by Mohr Marketing
MDL 3140: Is Your Intake Ready for the Depo-Provera Docket? In an era where some mass tort defendants are thinly capitalized or seeking bankruptcy protection, the Depo-Provera litigation offers a rare strategic advantage: Defendant Solvency. Pfizer, the primary defendant, holds massive liquidity, giving them the “muscle” to absorb a global settlement without existential risk to…
Continue reading Defendant Solvency and the Business Case for MDL 3140